YSB (HKG:9885) expects its H1 profit to rise more than three times year over year, according to a Hong Kong bourse filing Thursday.
Shares of the pharmaceutical retailer fell nearly 2% in recent Friday trade.
The company anticipates attributable profit of at least 70 million yuan for the six months ended June 30, compared to 21.8 million yuan in the year-ago period.
The company will likely post its results by the end of August.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.